chemieunternehmen.com

Evotec AG today announced the publication of its fourth DDup edition. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-4—epigenetics-5170

Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-hold-rd-day-2013-5169

Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-to-collaborate-on-exploration-of-enteroendocrine-signals-affecting-key-metabolic-pathways-5165

Evotec AG announces today the publication of a DDup Special Edition, which focuses on its drug discovery service offering. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-special-edition—drug-discovery-services-5158

Evotec AG today announced a strategic partnership with the Harvard Stem Cell Institute to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-stem-cell-institute-form-curemn-collaboration-to-advance-als-research-5157

Evotec AG today announced a 9.9% increase of its share capital.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-raises-eur-30-m-from-biotechnology-value-fund-5155

Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec’s assay development and screening capabilities to support the Jain Foundation’s goals of understanding and curing dysferlinopathy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-jain-foundation-announce-extension-of-research-collaboration-in-skeletal-muscular-dystrophy-diseases-5153

Evotec AG today reported financial results and corporate updates for the first half of 2013. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-h1-2013-results-5151

Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-dow-agrosciences-announce-collaboration-on-cellular-target-profiling-5147